Association of lipid metabolism with ovarian cancer

Current Oncology

Volumn 17, Issue 5, 2010, Pages 6-11

  Tania, M ^a   Khan, M A ^a   Song, Y ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cholesterol; Fatty acid synthase; Lipids; Metabolism; Ovarian cancer; Phospholipids

Indexed keywords

AUTOTAXIN; FATTY ACID SYNTHASE; LYSOPHOSPHATIDIC ACID; PHOSPHOLIPASE A2; PHOSPHOLIPASE D; PHOSPHOLIPID;

CANCER RISK; DISEASE ASSOCIATION; FAT INTAKE; GENE EXPRESSION REGULATION; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; METASTASIS; NONHUMAN; OVARY CANCER; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 78149423097     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i5.668     Document Type: Review

References (62)

1. Nelson DL, Cox MM. Bioenergetics and metabolism. In: Lehninger AL, Nelson DL, Cox MM, eds. Lehninger Principles of Biochemistry. 3rd ed. New York: Worth Publishers; 2000: 598-619,770-814.
2. Granados S, Quiles JL, Gil A, Ramírez-Tortosa MC. Dietary lipids and cancer [Spanish]. Nutr Hosp 2006;21:42-52.
3. Araki E. Dietary lipid intake and cancer [Japanese]. Bull Saitama Prefectural Univ 2000;1:89-97.
4. Halton JM, Nazir DJ, McQueen MJ, Barr RD. Blood lipid profiles in children with acute lymphoblastic leukemia. Cancer 1998;83:379-84.
5. Simo CE, Orti LA, Sena FF, Contreras BE. Blood cholesterol in patients with cancer [Spanish]. An Med Interna 1998;15:363-6.
6. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J Cell Biochem 2004;91:54-69.
7. Kolanjiappan K, Ramachandran CR, Manoharan S. Biochemical changes in tumor tissues of oral cancer patients. Clin Biochem 2003;36:61-5.
8. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003;101:3628-34.
9. Duncan RE, El-Sohemy A, Archer MC. Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. J Biol Chem 2004;279:33079-84.
10. El-Sohemy A, Archer MC. Inhibition of N-methyl-N-nitrosourea- and 7,12-dimethylbenz[a]anthracene-induced rat mammary tumorigenesis by dietary cholesterol is independent of Ha-Ras mutations. Carcinogenesis 2000;21:827-31.
11. Tabuchi M, Kitayama J, Nagawa H. Hypertriglyceridemia is positively correlated with the development of colorectal tubular adenoma in Japanese men. World J Gastroenterol 2006;12:1261-4.
12. McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 1994;3:687-95.
13. Daly PF, Lyon RC, Faustino PJ, Cohen JS. Phospholipid metabolism in cancer cells monitored by 31P nmr spectroscopy. J Biol Chem 1987;262:14875-8.
14. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 2003;90:525-33.
15. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm 2006;3:496-506.
16. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006;66:5977-80.
17. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 2009;101:519-32.
18. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010;140:49-61.
19. Risch HA, Jain M, Marrett LD, Howe GR. Dietary fat intake and risk of epithelial ovarian cancer. J Natl Cancer Inst 1994;86:1409-15.
20. Kushi LH, Mink PJ, Folsom AR, et al. Prospective study of diet and ovarian cancer. Am J Epidemiol 1999;149:21-31.
21. La Vecchia C, Decarli A, Negri E, et al. Dietary factors and the risk of epithelial ovarian cancer. J Natl Cancer Inst 1987;79:663-9.
22. Knekt P, Steineck G, Jarvinen R, Hakulinen T, Aromaa A. Intake of fried meat and risk of cancer: a follow-up study in Finland. Int J Cancer 1994;59:756-60.
23. Pan SY, Ugnat AM, Mao Y, Wen SW, Jhonson KC. A case- control study of diet and the risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1522-7.
24. Bertone ER, Rosner BA, Hunter DJ, et al. Dietary fat intake and ovarian cancer in a cohort of US women. Am J Epidemiol 2002;156:22-31.
25. Hill MJ, Goddard P, Williams RE. Gut bacteria and aetiology of cancer of the breast. Lancet 1971;2:472-3.
26. Bidoli E, La Vecchia C, Montella M, et al. Nutrient intake and ovarian cancer: an Italian case-control study. Cancer Causes Control 2002;13:255-61.
27. Taylor CG, Doering DL, Kraemer FB, Taylor DD. Aberrations in normal systemic lipid metabolism in ovarian cancer patients. Gynecol Oncol 1996;60:35-41.
28. Memon NQ, Memon JQ, Khan AW. Serum cholesterol levels and incidence of ovarian tumours in Pakistani women. Pak J Physiol 2007;3:23-5.
29. Delimaris I, Faviou E, Antonakos G, Stathopoulou E, Zachari A, Dionyssiou-Asteriou A. Oxidized ldl, serum oxidizability and serum lipid levels in patients with breast or ovarian cancer. Clin Biochem 2007;40:1129-34.
30. Helzlsouer KJ, Alberg AJ, Norkus EP, Morris JS, Hoffman SC, Comstock GW. Prospective study of serum micronutrients and ovarian cancer. J Natl Cancer Inst 1996;88:32-7.
31. Pirozzo S, Purdie D, Kuiper-Linley M, et al. Ovarian cancer, cholesterol, and eggs: a case-control analysis. Cancer Epidemiol Biomarkers Prev 2002;11:1112-14.
32. Woyengo TA, Ramprasath VR, Jones PJ. Anticancer effects of phytosterols. Eur J Clin Nutr 2009;63:813-20.
33. Li AJ, Elmore RG, Chen IY, Karlan BY. Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers. Gynecol Oncol 2010;116:78-81.
34. Ostroumova MN, Kovalenko IG, Bershtein LM, Tsyrlina EV, Dil'man VM. Characteristics of dyslipidemia in cancer patients [Russian]. Vopr Onkol 1986;32:34-43.
35. Gansler TS, Hardman W, Hunt DA, Schaffel S, Hennigar RA. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 1997;28: 686-92.
36. Pizer ES, Lax SF, Kuhajda FP, Pasternack GR, Kurman RJ. Fatty acid synthase expression in endometrial carcinoma. Cancer 1998;83:528-37.
37. Alò PL, Visca P, Framarino ML, et al. Immunohistochemical study of fatty acid synthase in ovarian neoplasms. Oncol Rep 2000;7:1383-8.
38. Menendez JA, Vellon L, Mehmi I, et al. Inhibition of fatty acid synthase (fas) suppresses her2/neu (ErbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A 2004;101:10715-20.
39. Zhou W, Han WF, Landree LE, et al. Fatty acid synthase inhibition activates amp-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res 2007; 67:2964-71.
40. El Meskini R, Medghalchi SM, Vadlamudi A, et al. Fatty acid synthase inhibition for ovarian cancer. Presented at the 99th Annual Meeting of the American Association for Cancer Research; San Diego, CA; April 15, 2008. [Available online at: www.fasgen.com/Fatty-Acid-Synthase-Inhibition-for- Ovarian-Cancer.pdf; cited July 21, 2010]
41. Ricci A, Podo EIF. Alterations of choline phospholipid metabolism in ovarian tumor progression: a nmr study. Biophy Bioeng Lett 2008;1:1-8.
42. Ross J, Najjar AM, Sankaranarayanapillai M, Tong WP, Kaluarachchi K, Ronen SM. Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine. Mol Cancer Ther 2008;7:2556-65.
43. Lu J, Xiao Y, Baudhuin LM, Hong G, Xu Y. Role of etherlinked lysophosphatidic acids in ovarian cancer cells. J Lipid Res 2002;43:463-76.
44. Moolenaar WH. Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res 1999;253:230-8.
45. Liscovitch M, Cantley LC. Lipid second messengers. Cell 1994;77:329-34.
46. Westermann AM, Havik E, Postma FR, et al. Malignant effusions contain lysophosphatidic acid (lpa)-like activity. Ann Oncol 1998;9:437-42.
47. Fang X, Yu S, Bast RC, et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 2004;279:9653-61.
48. Sivashanmugam P, Tang L, Daaka Y. Interleukin 6 mediates the lysophosphatidic acid-regulated cross-talk between stromal and epithelial prostate cancer cells. J Biol Chem 2004;279:21154-9.
49. Hu YL, Tee MK, Goetzl EJ, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 2001;93:762-8.
50. Pustilnik TB, Estrella V, Wiener JR, et al. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 1999;5:3704-10.
51. Symowicz J, Adley BP, Woo MM, Auersperg N, Hudson LG, Stack MS. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res 2005;65:2234-42.
52. Oyesanya RA, Lee ZP, Wu J, et al. Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid- induced cyclooxygenase-2 expression in ovarian cancer cells. FASEB J 2008;22:2639-51.
53. Fujita T, Miyamoto S, Onoyama I, Sonoda K, Mekada E, Nakano H. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett 2003;192:161-9.
54. Tanyi J, Rigó J Jr. Lysophosphatidic acid as a potential target for treatment and molecular diagnosis of epithelial ovarian cancers [Hungarian]. Orv Hetil 2009;150:1109-18.
55. Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, Fang X. Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Clin Cancer Res 2009;15:492-501.
56. Zhao X, Wang D, Zhao Z, et al. Caspase-3-dependent activation of calcium-independent phospholipase A2 enhances cell migration in non-apoptotic ovarian cancer cells. J Biol Chem 2006;281:29357-68.
57. Song Y, Wilkins P, Hu W, et al. Inhibition of calciumindependent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells. Biochem J 2007;406:427-36.
58. Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB. Constitutive and lysophosphatidic acid (lpa)-induced lpa production: role of phospholipase D and phospholipase A2. Clin Cancer Res 2000;6:2482-91.
59. Shen Y, Zheng Y, Foster DA. Phospholipase D2 stimulates cell protrusion in v-Src-transformed cells. Biochem Biophys Res Commun 2002;293:201-6.
60. Chae YC, Kim JH, Kim KL, et al. Phospholipase D activity regulates integrin-mediated cell spreading and migration by inducing gtp-Rac translocation to the plasma membrane. Mol Biol Cell 2008;19:3111-23.
61. Ptaszynska MM, Pendrak ML, Bandle RW, Stracke ML, Roberts DD. Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells. Mol Cancer Res 2008;6:352-63.
62. Gaetano CG, Samadi N, Tomsig JL, Macdonald TL, Lynch KR, Brindley DN. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Mol Carcinog 2009;48:801-9.